{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:00:50Z","timestamp":1780977650187,"version":"3.54.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107258","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:36:40Z","timestamp":1778945800000},"page":"107258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["After Parkinson\u2019s, does the GLP-1 hypothesis still hold in multiple sclerosis?"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7344-638X","authenticated-orcid":false,"given":"Mobeen","family":"Sajjad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7_Suppl_1","key":"10.1016\/j.msard.2026.107258_bib0004","article-title":"Exploring the effect of GLP-1 agonists on Multiple sclerosis disease progression","volume":"104","author":"Ali","year":"2025","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2026.107258_bib0005","article-title":"People with multiple sclerosis treated with Ocrelizumab and GLP-1 agonists","year":"2025","journal-title":"ClinicalTrials.gov."},{"key":"10.1016\/j.msard.2026.107258_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251408269","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"19","author":"Stefanou","year":"2026","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.msard.2026.107258_bib0003","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/13543784.2025.2587277","article-title":"Glucagon-like peptide-1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions","volume":"34","author":"Stuve","year":"2025","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"10479","key":"10.1016\/j.msard.2026.107258_bib0001","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3 trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:37:31Z","timestamp":1780976251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":5,"alternative-id":["S2211034826002944"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107258","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"After Parkinson\u2019s, does the GLP-1 hypothesis still hold in multiple sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107258"}}